Gemcitabine might be a second-line treatment option for patients with high-risk non-muscle-invasive bladder cancer (BC) who fail therapy with bacille Calmette-Guérin (BCG), according to Italian researchers.

BCG cut the risk of cancer-related death risk by 53% versus epirubicin.

It is associated with a higher risk of recurrence and death from upper tract urothelial carcinoma.

Lead exposure may be associated with the initiation and development of bladder cancer, according to a study conducted in Poland.

High levels of arsenic reduced mortality by 50% compared with low levels.

This approach has oncologic outcomes similar to that of standard cystoprostatectomy, study shows.

Researchers who analyzed genetic data from patients with bladder cancer discovered three common inherited genetic variants, also known as polymorphisms, which are significantly associated with development of this malignancy.

Two-year survival is similar to that achieved with cystectomy.

TORONTO—Substaging of bladder cancer tumors provides important prognostic information that could help guide patient management decisions, according to researchers.

Endo Pharmaceuticals, of Chadds Ford, Pa., has reintroduced Valstar (valrubicin) for the treatment of carcinoma in situ (CIS) of the urinary bladder that is refractory to treatment with Bacillus-Calmette-Guérin (BCG).